ScinoPharm Taiwan, a renowned API integrated service provider, announced that its revenue reached a record high of NT$567 million in December last year, with record revenue of NT$1.123 billion in the fourth quarter alone, thanks to several new generic drugs approved in the second half of last year. Revenue for 2023 reached NT$3.186 billion, comparable to last year. ScinoPharm's cumulative revenue last year generated nearly NT$3.2 billion, which is comparable to 2022.

Looking ahead to this year, of the 76 generic APIs developed by ScinoPharm, 37 have been approved; there are a total of 923 DMFs registered worldwide, of which 68 are in the US; there are more than 200 R&D projects commissioned by customers, of which 11 products (9 new drugs) have been approved for marketing and 6 products have entered Phase III; coupled with the fact that the company's API facilities have passed the official GMP quality inspections by the US FDA, Japan PMDA, EU EMA, EDQM, Australia TGA, Korea KFDA, Mexico COFEPRIS and Germany. Other affiliated sites have also demonstrated compliance with quality inspection standards set by the US, Japan, Europe, Australia, Korea, Mexico, Germany and Taiwan. This gives ScinoPharm a competitive edge to enter global markets.

In addition, ScinoPharm has APIs that complement approved generic drugs, including glaucoma, Alzheimer's disease, and genetic epilepsy and heart failure drugs developed on behalf of customers, all of which will benefit the company's API business in 2024.